案例报告:塞库金纽马布 (互乐金-17 抑制剂) 和性结肠炎爆发 - 双刃剑
Joaquin Ongay1,2, Ivanna Candel1, Alain Bitton1
1Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC, Canada.
塞库金纽马布是一种17A型干白素抑制剂,可能会在患有现有疾病的患者中引发炎症性肠病爆发. 这一案例凸显了在为牛皮关节炎等疾病开处IL-17A阻断剂时,医生需要提高意识的必要性.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 胃肠病学 胃肠病学
- 类风湿病学 类风湿病学
背景情况:
- 塞库金努马布是一种被批准用于治疗牛皮关节炎和结性脊柱炎的17A (IL-17A) 抑制剂.
- 以前的报道表明IL-17A抑制剂与炎症性肠病 (IBD) 爆发或新发病之间的联系.
研究的目的:
- 报告严重性结肠炎 (UC) 发作的病例,该病例发生在患者中,该患者因耐火性牛皮关节炎 (PsA) 接受了secukinumab治疗.
- 突出IL-17A阻塞在患有先前IBD的患者中的潜在不良事件.
主要方法:
- 一个56岁妇女的病例报告,她的UC病史处于缓解状态.
- 对临床表现的分析,治疗过程,以及在PSA治疗sequukinumab开始后的结果.
主要成果:
- 患者在开始使用secukinumab后经历了严重的UC爆发,并出现了广泛的和全身炎症.
- 需要住院治疗,治疗被转换为risankizumab.
结论:
- 在易受感染的个体中,IL-17A阻塞可能会导致或加剧IBD.
- 医生必须考虑IBD并发症的风险,在给有IBD病史的患者开处方IL-17A抑制剂时.
- 新的治疗方法可能是必要的,以管理这种严重的并发症.
更多相关视频
04:47Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
11:003D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
Published on: October 17, 2025
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Ulcerative Colitis
